Fludarabine
Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
Explore 10 assets in Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Astellas Pharma Global Development, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04240002CT.gov A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
NCT01760655CT.gov Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | Astellas Pharma Global Development, Inc. | P2 | B · 62 |
| Gilteritinib | The First Affiliated Hospital of Soochow University | P3 | BB |
| Azacitidine | French Innovative Leukemia Organisation | P2 | BB |
| Cytarabine | First Affiliated Hospital of Zhejiang University | P3 | BB |
| Sorafenib | The First Affiliated Hospital of Soochow University | P3 | BB |
| Daunomycin | Gruppo Italiano Malattie EMatologiche dell'Adulto | P3 | BB |
| xy0206 | Shijiazhuang Yiling Pharmaceutical Co. Ltd | P3 | BB |
| Quizartinib | M.D. Anderson Cancer Center | P2 | BB |
| Midostaurin | Gruppo Italiano Malattie EMatologiche dell'Adulto | P3 | B |
+13 more in the Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- GilteritinibThe First Affiliated Hospital of Soochow UniversityBB
- AzacitidineFrench Innovative Leukemia OrganisationBB
- CytarabineFirst Affiliated Hospital of Zhejiang UniversityBB
- SorafenibThe First Affiliated Hospital of Soochow UniversityBB
- DaunomycinGruppo Italiano Malattie EMatologiche dell'AdultoBB
Citation
Floatz Terminal. Fludarabine in Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-acute-myeloid-leukemia-flt3-internal-tandem-duplication
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →